These medications stimulate insulin secretion independent of glucose concentrations, creating potential for excessive insulin release when used alongside GLP-1 receptor agonists
Other Symptoms: Along with changes in menstrual bleeding, you may also notice other symptoms such as cramping, bloating, or mood changes
You get the potential glucose benefit, the routine advantage, and daytime appetite suppression alignment
Peak craving suppression typically occurs as your dose reaches therapeutic levels over 812 weeks
Metformin, though not a GLP-1 agonist, shares the property of reducing stomach acid and interfering with b12 absorption
clinicians should therefore not rely on population averages when evaluating a symptomatic individual